Sugi Predict

Sugi Predict / Compounds / SCHEMBL3420428

SCHEMBL3420428

SCHEMBL3420428

CC(C)CCn1c(O)c(C(=O)NCC(=O)O)c(=O)n(CCC(C)C)c1=O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EGLN3 Q9H6Z9 4/20 0.46
▸ EGLN1 Q9GZT9 6/20 0.44
▸ EGLN2 Q96KS0 2/20 0.44
▸ OGFOD1 Q8N543 1/20 0.44
▸ HIF1AN Q9NWT6 1/20 0.44
▸ APEX1 P27695 1/20 0.39
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ EGFR P00533 1/20 0.37
▸ SRC P12931 1/20 0.37
▸ MEN1 O00255 2/20 0.37
▸ KMT2A Q03164 2/20 0.37
▸ NPC1 O15118 1/20 0.37
▸ HIF1A Q16665 3/20 0.35
▸ ALDH1A1 P00352 3/20 0.35
▸ HPGD P15428 2/20 0.35
▸ KDM4E B2RXH2 1/20 0.35
▸ LMNA P02545 1/20 0.35
▸ HTT P42858 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ PDE2A O00408 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3422969 0.85 EGLN3 (0.47) EGLN3EGLN1EGLN2OGFOD1HIF1AN
SCHEMBL3420455 0.84 EGLN3 (0.46) EGLN3EGLN1EGLN2OGFOD1HIF1AN
SCHEMBL3415785 0.82 EGLN3 (0.44) EGLN3EGLN1EGLN2OGFOD1HIF1AN
SCHEMBL4065069 0.79 EGLN1 (0.41) EGLN3EGLN1EGLN2MEN1KMT2A
SCHEMBL3421145 0.79 HIF1A (0.52) EGLN3EGLN1EGLN2OGFOD1HIF1AN
SCHEMBL4991904 0.78 EGLN3 (0.41) EGLN3EGLN1APEX1L3MBTL1EGFR
SCHEMBL3424036 0.77 EGLN1 (0.48) EGLN3EGLN1EGLN2OGFOD1HIF1AN
SCHEMBL8244097 0.76 EGLN1 (0.69) EGLN1L3MBTL1MEN1KMT2ANPC1
SCHEMBL3419394 0.74 EGLN3 (0.66) EGLN3EGLN1EGLN2MEN1KMT2A
SCHEMBL8248071 0.73 HIF1A (0.56) EGLN3EGLN1L3MBTL1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200157055-A1 Prolyl Hydroxylase Inhibitors GLAXOSMITHKLINE LLC (US) 2020-05-21 — — US claimed
EP-2037922-B9 PROLYL HYDROXYLASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2017-08-23 — — EP claimed
EP-2037922-B1 PROLYL HYDROXYLASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2014-01-22 — — EP claimed
US-8324208-B2 Prolyl hydroxylase inhibitors GLAXOSMITHKLINE LLC (US) 2012-12-04 — — US claimed
US-20100113444-A1 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION 2010-05-06 — — US claimed
US-20230227414-A1 Prolyl Hydroxylase Inhibitors GLAXOSMITHKLINE LLC (US) 2023-07-20 — — US disclosed
US-20230227414-A1 Prolyl Hydroxylase Inhibitors GLAXOSMITHKLINE LLC (US) 2023-07-20 — — US disclosed
US-20230227414-A1 Prolyl Hydroxylase Inhibitors GLAXOSMITHKLINE LLC (US) 2023-07-20 — — US disclosed
US-11643397-B2 Prolyl hydroxylase inhibitors GLAXOSMITHKLINE LLC (US) 2023-05-09 — — US disclosed
US-11643397-B2 Prolyl hydroxylase inhibitors GLAXOSMITHKLINE LLC (US) 2023-05-09 — — US disclosed
US-11643397-B2 Prolyl hydroxylase inhibitors GLAXOSMITHKLINE LLC (US) 2023-05-09 — — US disclosed
US-20210347740-A1 Prolyl Hydroxylase Inhibitors GLAXOSMITHKLINE LLC (US) 2021-11-11 — — US disclosed
US-20130072487-A1 PROLYL HYDROXYLASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2013-03-21 — — US disclosed
US-20130072487-A1 PROLYL HYDROXYLASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2013-03-21 — — US disclosed
US-8324208-B2 Prolyl hydroxylase inhibitors GLAXOSMITHKLINE LLC (US) 2012-12-04 — — US disclosed
US-8324208-B2 Prolyl hydroxylase inhibitors GLAXOSMITHKLINE LLC (US) 2012-12-04 — — US disclosed
US-8324208-B2 Prolyl hydroxylase inhibitors GLAXOSMITHKLINE LLC (US) 2012-12-04 — — US disclosed
US-20100113444-A1 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION 2010-05-06 — — US disclosed
US-20100113444-A1 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION 2010-05-06 — — US disclosed
US-20100113444-A1 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION 2010-05-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11643397-B2 Prolyl hydroxylase inhibitors HIF1AN, EGLN3, EGLN2 EGLN3 2/4885EGLN1 6/4885EGLN2 3/4885
US-20210347740-A1 Prolyl Hydroxylase Inhibitors HIF1AN, EGLN3, EGLN2 EGLN3 2/4885EGLN1 6/4885EGLN2 3/4885
US-20130072487-A1 PROLYL HYDROXYLASE INHIBITORS HIF1AN, EGLN3, EGLN2 EGLN3 2/4885EGLN1 6/4885EGLN2 3/4885
US-20100113444-A1 PROLYL HYDROXYLASE INHIBITORS HIF1AN, EGLN3, EGLN2 EGLN3 2/4885EGLN1 6/4885EGLN2 3/4885
US-20200157055-A1 Prolyl Hydroxylase Inhibitors HIF1AN, EGLN3, EGLN2 EGLN3 2/4885EGLN1 6/4885EGLN2 3/4885
US-20230227414-A1 Prolyl Hydroxylase Inhibitors HIF1AN, EGLN3, EGLN2 EGLN3 2/4885EGLN1 6/4885EGLN2 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.